

CLAIMS

1. Use of a composition in a non-hormonal contraception method for a male subject, wherein said composition is an extended release formulation comprising:
 - 5 - an alpha-1-adrenoreceptor antagonist; and
 - at least one pharmaceutically acceptable carrier,wherein the contraception method includes a once daily administration of said composition at about the same time each day, triggering a continuous reversible aspermia, azoospermia, or severe oligozoospermia in the male subject, and
10 wherein after an initial period of at least two consecutive days, the contraception is not impaired by a delay of the subsequent once daily intake.
2. The use according to claim 1, wherein the composition is administered orally.
3. The use according to claim 1 or claim 2, wherein, after the initial period of consecutive days, the intake of a next dose can be delayed from 6 to 18 hours after
15 the last regular daily dose time, and the condition of aspermia, azoospermia or severe oligozoospermia is maintained in the male subject.
4. The use according to any one of claims 1 to 3, wherein after the initial period of consecutive days, failure to intake one daily dose does not affect the continuous state of aspermia, azoospermia or severe oligozoospermia supporting the
20 contraception method for 36 to 48 hours as of the last intake time.
5. The use according to any one of claims 1 to 4, wherein the contraception method is carried on for at least eight days.
6. The use according to any one of claims 1 to 5, wherein the alpha-1-adrenoreceptor antagonist is in an amount ranging from about 0.1 to about 30 mg, preferably from
25 about 0.2 to about 20 mg.
7. The use according to any one of claims 1 to 6, wherein the alpha-1-adrenoreceptor antagonist is (*R*)-silodosin.

8. The use according to any one of claims **1** to **7**, wherein (*R*)-silodosin is in a polymorphic or amorphous form.
9. The use according to any one of claims **1** to **8**, wherein the composition is formulated in an extended release formulation.
- 5 10. The use according to any one of claims **1** to **9**, wherein the composition includes or consists of at least one particle, preferably at least one coated particle, and the average particle diameter is in the range of 0.01 to 5 mm, preferably 0.1 to 2 mm.
11. The use according to any one of claims **1** to **10**, wherein the particles are encompassed into a capsule, each capsule being filled by particles in a number
10 sufficient to reach the daily dose.
12. The use according to any one of claims **1** to **11**, wherein the contraception is achieved independently from the food consumption by the male subject.
13. The use according to any one of claims **1** to **12**, wherein the daily administration
15 contraception method further comprises a simultaneous or sequential administration of an additional composition suitable for treating erectile dysfunction; preferably the additional composition comprises a phosphodiesterase-5 inhibitor.
14. Packaging comprising at least 7, 14, 28, 56, 84, or 168 to 365 unitary doses; or 10, 20, 30, 60, 90, or 180 to 360 unitary doses of the composition described in any one
20 of claims **1** to **12**, each unitary dose being a daily dose.
15. Packaging according claim **14**, wherein the composition includes an alpha-1-adrenoreceptor antagonist in an amount ranging from about 0.1 to about 30 mg, preferably from about 0.2 to about 20 mg, preferably the alpha-1-adrenoreceptor antagonist is (*R*)-silodosin in an amount of 8 to 12 mg.